All Resources
Paper Summary
Improving Adoptive Cell Transfer: New Combinations for Greater Efficacy

In a paper published in Nature Communications, Parisi et al. from the University of California described how the novel agonist NKTR-214 outperforms IL-2 for improving ACT anti-tumor efficacy, identifying specific biomarkers that corresponded to increased response using our functional proteomics-based cellular characterization.

What's Inside

In this Paper Summary we discuss:

A next-generation agonist for improving persistence and limiting tumor growth
Full cellular characterization of immune cells
NKTR-214 dramatically increases T cell polyfunctionality, a correlate to persistence
A Deeper Look

More about this Paper Summary

Improving Persistence and Limiting Tumor Growth

Adoptive cell transfer (ACT) is a promising therapeutic approach in the fight against cancer.

Conventionally in this therapy, patients receive tumor-infiltrating lymphocytes (TILs) or T cell receptor (TCR)-engineered blood T cells, along with high doses of interleukin-2 (IL-2) to support the expansion and function of the transferred cells.

However, IL-2-induced toxicity and immunosuppression pose problems for patients, limiting the clinical use of ACT. Parisi et al. utilized our functional proteomics-based cellular characterization to overcome these challenges.

Download this Paper Summary to learn more!

Get the Paper Summary
Back to the Top